VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CCELCryo-Cell International, Inc.
$3.17$26M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksCCELBalance Sheet

Cryo-Cell International, Inc. (CCEL) Balance Sheet

30Y historyFree accessUpdated daily

The company's financial position is severely constrained by a negative equity deficit of $18.4 million and a precarious current ratio of 0.62 as of 2026Q1.

CCEL Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMNov'25Nov'24Nov'23Nov'22Nov'21Nov'20Nov'19Nov'18Nov'17Nov'16Nov'15Nov'14Nov'13Nov'12Nov'11Nov'10Nov'09Nov'08Nov'07Nov'06Nov'05Nov'04Nov'03Nov'02Nov'01Nov'00Nov'99Nov'98Nov'97Nov'96
Total Current Assets11.08M11.76M12.55M9.45M9.61M15.78M18.56M15.39M29.54M12.74M9.01M10.35M8.49M9.43M9.32M14.05M12.88M10.95M7.34M7.59M10.51M10.45M7.42M4.4M6.16M7.96M3.88M2.4M1M1.2M1.8M
Cash & Short-Term Investments2.9M3.3M3.5M980.25K1.72M8.34M10.45M7.45M6.92M6.72M4.12M4.76M3.38M3.93M2.68M7.31M9.5M7.81M4.69M4.37M8.4M8.46M5.52M3.25M5.06M5.8M3.13M1.7M500K800K1.1M
Cash Only249.67K319.03K560.96K406.07K1.7M8.26M10.36M6.54M6.04M6.28M3.5M4.15M3.28M3.93M2.68M6.31M8.37M6.85M3.57M3.36M7.41M7.98M4.74M2.45M1.94M5.54M2.7M1.6M500K800K1.1M
Short-Term Investments2.65M2.98M2.94M574.18K17.62K75.41K88.48K904.05K875.69K439.32K624.22K610.42K102.67K001M1.13M960K1.13M1M989.58K484.49K782.42K798.08K3.13M261K429.43K100K000
Accounts Receivable6.82M6.85M7.31M6.58M6.04M5.25M6.32M6.1M5.87M5.13M4.05M3.06M4.07M3.89M3.4M3.06M2.36M2.25M1.91M2.43M1.21M1.04M1.28M778.95K301.91K1.89M580.75K600K200K100K700K
Days Sales Outstanding60.0779.1683.4176.5872.7266.3874.0969.9573.373.763.9652.9373.8574.769.0962.3248.7650.2240.2850.8325.7826.3638.1537.6615.58121.83100.49128.82243.3391.2594.63
Inventory356.99K408.79K657.7K768.88K851.23K921.21K927.32K1.08M16.04M314.57K361.14K475.61K914.89K000000000000000000
Days Inventory Outstanding27.1620.2330.233.2435.3437.435.0539.44685.417.0722.8330.8359.29------------------
Other Current Assets609.55K633.99K454.6K512.06K426.88K711.21K244.7K260.4K254.47K206.14K78.45K1.63M263.52K1.12M2.58M2.91M367.92K215K221K218K245K245K341K000174.82K100K300K300K0
Total Non-Current Assets49.81M49.97M52.12M51.77M55.28M44.88M27.64M27.5M12.85M11.17M10.53M9.14M1.72M2.08M3.02M5.41M5.28M3.65M3.63M4.05M4.13M3.79M4.22M2.82M7.7M9.43M4.36M3.1M3.1M2.8M2.4M
Property, Plant & Equipment21.59M21.85M22.7M22.03M14.21M4.15M1.94M1.85M1.49M882.38K979.46K879.07K953.41K1.21M1.28M1.54M2.22M2.37M2.57M3.12M3.19M2.92M2.82M1.35M2.63M3.18M3.02M2.7M2.4M2.5M2M
Fixed Asset Turnover1.43x1.44x1.41x1.42x2.14x6.97x16.06x17.23x19.57x28.77x23.61x23.99x21.11x15.73x14.03x11.63x7.94x6.89x6.72x5.60x5.39x4.94x4.33x5.57x2.69x1.77x0.70x0.63x0.13x0.16x1.35x
Goodwill1.94M1.94M1.94M1.94M1.94M1.94M1.94M1.94M1.94M001.78M0000000000000000000
Intangible Assets851.92K863.07K921.25K989.12K15.15M16.21M1.53M1.25M1.34M226.42K261K516.33K28.36K003.06M02.25M1.91M00000102.34K119.66K108.67K100K100K100K100K
Long-Term Investments0000308K308K308K308K308K000684K721.91K697.66K690.4K690.4K690.4K690.4K1M1M1M484.49K468.1K0000000
Other Non-Current Assets1.8M1.69M5.76M6.31M9.92M10.26M11.56M13.07M113.89K28.89K25.5K40.61K51.85K146.12K1.04M558.25K756.28K501.92K282.12K930.94K939.46K863.08K909.88K998.86K4.96M6.13M1.23M300K600K200K300K
Total Assets60.88M61.73M64.68M61.22M64.89M60.66M46.2M42.89M42.39M23.91M19.54M19.5M10.21M11.5M12.33M19.47M18.16M14.61M10.97M11.63M14.64M14.23M11.64M7.22M13.86M17.39M8.24M5.5M4.1M4M4.2M
Asset Turnover0.50x0.51x0.49x0.51x0.47x0.48x0.67x0.74x0.69x1.06x1.18x1.08x1.97x1.65x1.46x0.92x0.97x1.12x1.57x1.50x1.17x1.02x1.05x1.05x0.51x0.32x0.26x0.31x0.07x0.10x0.64x
Asset Growth %-6.63%-4.56%5.65%-5.65%6.97%31.3%7.73%1.17%77.29%22.37%0.21%90.98%-11.23%-6.73%-36.66%7.18%24.33%33.13%-5.68%-20.54%2.86%22.27%61.29%-47.94%-20.3%111.16%49.77%34.15%2.5%-4.76%-
Total Current Liabilities17.76M19.79M21.6M20.86M19.48M21.07M16.41M15.43M15.43M13.94M13.11M10.42M9.13M9.81M10.66M10.56M8.27M8.33M6.67M7.29M6.51M4.93M4.59M4.23M1.52M831.83K278.81K200K1.7M900K500K
Accounts Payable3.3M2.87M1.88M3.17M1.61M1.49M957.39K1.37M1.26M1.93M1.49M1.33M992.91K1.19M1.21M1.01M1.05M750.13K835.67K1.89M1.21M478.57K482.7K340.73K391.27K114.94K92.91K0300K300K100K
Days Payables Outstanding142.74142.0586.44137.2566.6460.4936.1849.7953.93104.6893.8986.1264.3581.9490.3483.485.3360.4149.89104.7472.6242.1655.747.3857.2425.3340.99-547.5-121.67
Short-Term Debt2.03M2.73M3.69M1.39M2.42M1.9M3.1M3.1M000307.42K0002.32M0000000145K1.41K468.51K3.12K200K1.1M500K0
Deferred Revenue (Current)38.4M9.73M9.79M9.7M9.59M9.36M9.18M8.88M8.37M7.43M7.07M6.78M6.66M6.81M6.54M6.27M5.6M5.45M4.61M4.06M3.59M3.28M2.77M2.11M1.02M-467K00000
Other Current Liabilities191.09K4.46M1.42M1.2M1.98M4.96M003.1M2M2M0000-1.34M125.76K0330.36K00000190.07K0182.78K0300K100K400K
Current Ratio0.62x0.59x0.58x0.45x0.49x0.75x1.13x1.00x1.91x0.91x0.69x0.99x0.93x0.96x0.87x1.33x1.56x1.31x1.10x1.04x1.62x2.12x1.62x1.04x4.05x9.57x13.92x12.00x0.59x1.33x3.60x
Quick Ratio0.60x0.57x0.55x0.42x0.45x0.71x1.07x0.93x0.87x0.89x0.66x0.95x0.83x0.96x0.87x1.33x1.56x1.31x1.10x1.04x1.62x2.12x1.62x1.04x4.05x9.57x13.92x12.00x0.59x1.33x3.60x
Cash Conversion Cycle-55.51-42.6627.17-27.4341.4143.372.9659.6704.77-13.91-7.1-2.3768.79------------------
Total Non-Current Liabilities61.52M60.54M56.29M51.39M46.93M35.4M32.45M34.41M35.87M22.47M21.84M14.04M11.81M10.96M10.66M11.36M11.44M11.46M11.28M10.94M10.23M8.91M7.89M6.78M2.47M2.04M1.32M300K100K800K100K
Long-Term Debt368.94K474.63K8.31M8.43M8.58M02.84M0000868.95K002.3M2.85M0286.44K382.85K000000014.53K0000
Capital Lease Obligations739.77K474.63K505.05K851.94K313.3K610.99K23.63K0000000000000000007.58K00000
Deferred Tax Liabilities0000000000000000015K21K18K45K45K000000000
Other Non-Current Liabilities61.15M60.07M922.02K919.23K2.04M3.52M2.38M10.78M15.55M6.72M9.24M2.3M2.3M2.3M003.93M3.75M3.75M10.92M4.31M4.41M5M5.09M2.47M2.03M1.31M300K100K00
Total Liabilities79.29M80.33M77.89M72.25M66.41M56.48M48.87M49.84M51.3M36.41M34.95M24.46M20.94M20.77M21.33M21.93M19.71M19.79M17.95M18.22M16.73M13.84M12.48M11.01M4M2.87M1.6M500K1.8M900K500K
Total Debt2.4M3.2M12.93M10.9M11.61M2.82M6.24M8.96M12.94M7.3M9.82M1.18M2.3M2.3M2.3M3.75M1.62B2.13B1.23B1.33B1.71B1.17B145K145K1.41K476.09K17.65K200K1.1M500K0
Net Debt2.15M2.89M12.37M10.49M9.91M-5.44M-4.12M2.42M6.9M1.02M6.32M-2.98M-979.27K-1.63M-377.38K-2.56M1.61B2.12B1.22B1.33B1.7B1.16B-4.59M-2.31M-1.93M-5.06M-2.68M-1.4M600K-300K-1.1M
Debt / Equity-0.13x----0.67x---------------2970.03x--0.00x0.03x0.00x0.04x0.48x0.16x-
Debt / EBITDA1.55x0.52x3.26x-1.99x0.53x0.75x1.64x2.35x1.39x13.63x0.37x0.98x1.10x-12.37x426.36x909.00x3488.98x--643.40x0.04x--17.81x-----
Net Debt / EBITDA1.39x0.46x3.12x-1.70x-1.02x-0.50x0.44x1.25x0.19x8.77x-0.94x-0.42x-0.77x--8.43x424.16x906.08x3478.83x--639.02x-1.20x---189.41x-----1.22x
Interest Coverage-0.38x-0.13x0.50x-9.81x3.18x2.89x4.26x2.99x3.34x3.78x-1.62x1.73x1.59x1.14x-3.32x-0.32x2.62x2.09x0.53x-3.36x-2.92x1.42x4.24x-10.34x-101.32x-46.35x-976.97x--22.00x--
Total Equity-18.4M-18.61M-13.22M-11.03M-1.52M4.18M-2.67M-6.95M-8.91M-12.5M-15.41M-4.96M-10.73M-9.27M-9M-2.46M-1.55M-5.18M-6.98M-6.59M-2.09M394.56K-835.75K-3.79M9.87M14.52M6.64M5M2.3M3.1M3.7M
Equity Growth %-166.35%-40.78%-19.81%-623.69%-136.43%257%61.67%21.95%28.75%18.89%-210.51%53.72%-15.74%-3%-265.71%-58.68%70.07%25.76%-5.88%-215.02%-630.25%147.21%77.95%-138.42%-32.05%118.84%32.71%117.39%-25.81%-16.22%-
Book Value per Share-2.28-2.31-1.61-1.32-0.180.50-0.33-0.83-1.19-1.63-1.90-0.51-1.03-0.84-0.80-0.21-0.13-0.44-0.60-0.57-0.180.03-0.07-0.330.871.370.680.610.320.450.52
Total Shareholders' Equity-18.4M-18.61M-13.22M-11.03M-1.52M4.18M-2.67M-6.95M-8.91M-12.5M-15.41M-4.96M-10.73M-9.27M-9M-2.46M-1.55M-5.18M-6.98M-6.59M-2.09M394.56K-835.75K-3.79M9.57M14.52M6.64M5M2.3M3.1M3.7M
Common Stock148.77K148.77K148.7K148.49K148.48K146.66K136.34K135.99K135.96K129K125.04K122.6K119.21K118.7K118.6K118.53K117.53K117.53K117.5K116.72K116.25K116.25K113.97K113.52K113.52K113.28K101.33K100K000
Retained Earnings-38.39M-38.44M-32.78M-31.16M-21.64M-16.74M-18.82M-22.44M-25.33M-24.47M-26.79M-25.47M-33.58M-33.73M-33.75M-27.44M-25.9M-29.31M-30.88M-30.19M-25.19M-22.38M-23.41M-26.55M-13.26M-7.93M-8.83M-7.3M-6.8M-4.5M-2.9M
Treasury Stock-25.03M-25.03M-24.86M-23.43M-22.63M-20.81M-20.56M-20.56M-19.57M-19.57M-19.12M-8.32M-5.11M-2.93M-2.19M-484.54K-484.54K-484.54K-807.02K-807.02K-839.3K-839.3K-839.3K-535.91K0000000
Accumulated OCI00000000340.98K40.87K34.41K169.93K-5.92M-5.57M-5.3M0-94.06K-94.06K-94.06K-118.62K-111.88K-274.83K-130.25K-111.52K-170.32K42.5K26.93K-100K-100K0-100K
Minority Interest000000000000000000000000298.39K000000

Key Metrics

Growth RegimeDecelerating
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Critical liquidity and insolvency

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Persistent Erosion of Equity Base

According to the latest quarterly balance sheet data, CCEL's equity position has deteriorated into a negative $18.4 million deficit as of 2026Q1, reflecting a multi-year trend of accumulated losses that significantly undermines the company's long-term financial stability and overall net worth for shareholders.

The consistent decline in retained earnings, which reached negative $38.4 million in the most recent period, suggests that the company is failing to generate sufficient returns to offset its operational costs. This trajectory indicates that the business model is currently unable to sustain its capital structure without external support or a fundamental shift in profitability.

Leverage Volatility Amid Capital Constraints

Based on reported financial statements, CCEL's total debt levels have fluctuated significantly, peaking at $15.8 million in 2025Q2 before retreating to $2.4 million by 2026Q1, a pattern that suggests management is struggling to maintain a stable financing strategy while navigating severe cash flow pressures.

The rapid reduction in debt levels appears to be a reactive measure to preserve liquidity rather than a strategic deleveraging event. Investors should monitor whether this debt reduction limits the company's ability to fund necessary R&D or operational requirements for its clinical-stage initiatives.

Precarious Liquidity and Operational Runway

As indicated by the most recent quarterly filings, CCEL maintains a current ratio of 0.62 and a cash balance of only $249,700, which highlights a severe liquidity shortfall that leaves the company with virtually no buffer against unexpected operational shocks or further revenue contraction.

The consistently low current ratio, which has remained below 0.70 for the past ten quarters, implies that the company is perpetually reliant on incoming cash flows to meet its immediate obligations. This lack of working capital suggests that the firm is operating in a state of constant financial distress.

Deferred Revenue Distorts Solvency Perception

Data from recent SEC filings reveals that while deferred revenue remains substantial at $9.4 million, this liability represents a long-term service obligation rather than a cash-generating asset, potentially masking the true extent of the company's insolvency risk when viewed alongside its negative equity position.

The reliance on deferred revenue as a significant component of the liability structure suggests that the company is effectively 'borrowing' from future service delivery to fund current operations. This accounting reality warrants further investigation into whether the company can fulfill these long-term storage commitments given its current cash-constrained environment.

CCEL — Frequently Asked Questions

Quick answers to the most common questions about buying CCEL stock.

What are the total assets of Cryo-Cell International, Inc. (CCEL)?

As of 2025, Cryo-Cell International, Inc. (CCEL) had total assets of $61.7M including $11.8M in current assets.

How much debt does Cryo-Cell International, Inc. (CCEL) have?

Cryo-Cell International, Inc. (CCEL) carries total debt of $3.2M, offset by $3.3M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Cryo-Cell International, Inc.?

Cryo-Cell International, Inc. (CCEL) has total shareholders' equity (book value) of $-18.6M ($-2.31 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Cryo-Cell International, Inc.'s current ratio and liquidity?

Cryo-Cell International, Inc. (CCEL) reported a current ratio of 0.59x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.